EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSOJAG00000015308
Gene Symbol: DHCR24
1 Cross references
208 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSOJAG00000010070
Gene Symbol: HMGCR
1 Cross references
195 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase B

Ensembl ID : ENSOJAG00000007200
Gene Symbol: HMGCRB
1 Cross references
205 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1b

Ensembl ID : ENSOJAG00000020572
Gene Symbol: PDPK1B
1 Cross references
221 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase B

Ensembl ID : ENSOJAG00000010289
Gene Symbol: HPDB
1 Cross references
204 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSOJAG00000012499
Gene Symbol: NT5E
1 Cross references
215 Possible Orthologues:

5'-Nucleotidase, Ecto (Cd73)

Ensembl ID : ENSOJAG00000019656
Gene Symbol: NT5E
1 Cross references
180 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSOJAG00000004851
Gene Symbol: HTR1AB
1 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSOJAG00000024173
Gene Symbol: HTR2B
1 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSOJAG00000006996
Gene Symbol: HTR2CL1
1 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSOJAG00000004611
Gene Symbol: HTR5AB
1 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSOJAG00000013616
Gene Symbol: HTR1B
1 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).